ERBB2 and cancer: For example, novel targeted therapy agents can be used in patients with human epidermal growth factor receptor 2-positive (HER2+) cancers that are not responding to the standard regimen, and in patients with triple-negative (TN) diseases, lack of response could justify treatment escalation.